Medical AI

As Alexandria grapples with a documented mental health crisis, a new clinic introduces advanced TMS and ketamine therapies to a region burdened by long waits.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

MiniMed and Abbott are partnering on a dual glucose-ketone sensor, a move that could shift diabetes care from crisis management to proactive DKA prevention.

Precision Cardiovascular adds serial entrepreneur Brian Fahey to its board, signaling a push to commercialize its implantable SAW sensor and AI platform.

A new partnership embeds quantum-resilient security into AI robotics, signaling a strategic maneuver to preempt future threats and dominate a new era of compliance.

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

Mindray's new Hepatus-Series goes beyond a simple product launch, integrating AI-driven elastography to transform GI diagnostics and challenging market norms.

As one major allergy drug exits, a biotech startup is testing a new path: a microneedle skin stamp. Is this the future of allergy treatment?

An Israeli-American tech firm just put AI eyes on a US Black Hawk, pioneering a new era of visual predictive maintenance that could transform aviation safety.

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

The Dallas Cowboys are using a new device to build muscle. It’s part of a high-stakes trend where technology is redefining athlete recovery and longevity.

With dual FDA clearances secured, Rhythm AI appoints serial acquirer Mike Dineen as CEO, signaling a strategic pivot from innovation to market conquest.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

Amidst AI hype, one company is betting on human expertise. Conscientia Health's clinician-led AI platform is making bold promises for mental healthcare.

A new AI platform, HeartFocus Link, connects to existing hospital ultrasound carts, offering guided training to help close a critical skill gap in cardiac imaging.

Gene Solutions' SPOT-MAS 10 test gains FDA Breakthrough Designation, accelerating its path to the U.S. market and heralding a new era in early cancer detection.